GatewayC is an online cancer education platform funded by Health Education England. The content has been developed by clinical and educational experts to assist primary care professionals. It supports the NHS agenda of improving early cancer diagnosis, increasing cancer survival, and enhancing patient experience.
GatewayC provides evidence-based interactive online courses, live and on-demand webinars, bite-sized investigative reports of key issues in cancer care, mind maps to help identify the correct cancer pathways and other useful resources supporting improved outcomes and faster cancer diagnosis standards.
GatewayC has been shown to:
- Improve knowledge of cancer symptoms
- Increase professionals’ confidence in decision-making, regarding when to and when not to refer a patient
- Improve the quality of suspected cancer referrals, reducing delays in the system
- Improve communication to enhance the patient experience and support patients at each stage of their cancer journey
All courses are accredited by the RCGP and follow NICE NG12 guidance.
GatewayC was developed and funded as a project of the Greater Manchester Cancer Vanguard Programme, relying on support from a network of cancer education partners in Greater Manchester and Eastern Cheshire. The vanguard innovation programme in Greater Manchester was overseen by the Greater Manchester Cancer Board, reporting to the devolved Greater Manchester Health and Social Care Partnership and in turn to NHS England New Care Models team.
In 2017, GatewayC was piloted with primary care users in Greater Manchester and Eastern Cheshire. Courses were also piloted with UCLH Cancer Collaborative, a London Cancer Vanguard partner. Following a successful pilot, the GatewayC programme has now expanded, with 22 cancer courses available and more courses currently under development.
The pilot proved GatewayC’s relevance, usefulness and applicability to GPs, GP trainees and practice nurses. Objective evidence showed changes in confidence and ability to apply NICE guidance. GatewayC continues to be evaluated, to ensure it remains clinically relevant.